The health savings account-eligible design may decrease costs and utilization, but it also may decrease use of preventive services.
John M. Brooks, PhD
Advertisement
Articles by John M. Brooks, PhD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Advertisement
Latest Updated Articles
- Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression
Published: September 15th 2008 | Updated:
- Effects of Health Savings Account Eligible Plans on Utilization and Expenditures
Published: January 29th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5
